VP, public affairs, Gilead
Sonia Choi’s five years at Gilead Sciences have been memorable ones.
During that time, the company has enjoyed an amazing run of success, courtesy of groundbreaking hepatitis C cures Sovaldi and Harvoni. During her tenure, Gilead has also launched Yescarta, its first CAR-T therapy, and grown its HIV portfolio with Biktarvy.
Choi began her Gilead career working in public affairs in the EMEA region, starting as a senior director and eventually becoming EMEA VP for public affairs.
In the summer of 2016, Choi returned stateside and eased into her current role as VP of public affairs.
Before arriving at Gilead, Choi spent seven years at Bristol-Myers Squibb.
There, she held roles including public affairs director, director of international communications and public affairs, and executive director of global and U.S. brand communications. Earlier in her career, Choi worked for several blue chip agencies, including GCI Health, Ruder Finn, and FleishmanHillard.